Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
2020-06-17
Lassen Therapeutics today announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology. The Series A financing was led by Frazier Healthcare Partners (Frazier) with participation from Alta Partners and Longwood Fund.